On September 9, it was revealed in an SEC filing that Kumar Budur, Chief Medical Officer at Harmony Biosciences Hldgs (NASDAQ:HRMY) executed a significant exercise of company stock options.
What Happened: Budur, Chief Medical Officer at Harmony Biosciences Hldgs, exercised stock options for 22,954 shares of HRMY stock. This information was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The exercise price of the options was $30.49 per share.
Harmony Biosciences Hldgs shares are currently trading down by 1.57%, with a current price of $41.95 as of Thursday morning. This brings the total value of Budur's 22,954 shares to $262,978.
About Harmony Biosciences Hldgs
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Financial Milestones: Harmony Biosciences Hldgs's Journey
Revenue Growth: Harmony Biosciences Hldgs displayed positive results in 3 months. As of 30 June, 2026, the company achieved a solid revenue growth rate of approximately 30.32%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Interpreting Earnings Metrics:
-
Gross Margin: The company excels with a remarkable gross margin of 75.81%, indicating superior cost efficiency and profitability compared to its industry peers.
-
Earnings per Share (EPS): Harmony Biosciences Hldgs's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 1.3.
Debt Management: Harmony Biosciences Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.15, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Evaluating Valuation:
-
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 13.47, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
-
Price to Sales (P/S) Ratio: The Price to Sales ratio is 2.54, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
-
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Harmony Biosciences Hldgs's EV/EBITDA ratio at 6.82 suggests potential undervaluation, falling below industry averages.
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Understanding the Significance of Insider Transactions
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
The Insider's Guide to Important Transaction Codes
Surveying the realm of stock transactions, investors often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Harmony Biosciences Hldgs's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
